PCI The Journeys Within

Current Edition

Frankfurt 2027 – 12/10/26
ramusmedical

Last-Mile Hurdles in Putting AI into Real-World Clinical Research

Implementing an artificial intelligence (AI) policy at the highest levels of a clinical research organization requires middle managers empowered and equipped to carry it out companywide. But not every AI workflow deserves the same level of scrutiny, according to Marc Wartenberger, vice president of compliance and security at CRIO, who moderated a panel discussion on the policy-to-practice issues at the recent SCOPE Europe event in Barcelona. 

Personal productivity tools are far less concerning than those looking at adverse events or a clinical trial value informing a go/no-go decision on a drug treatment, he says. In this heavily regulated space, the focus is on maintaining Good Clinical Practice (GCP) compliance and data integrity. Risk-based workflows and a risk-proportionate approach are core pillars of the updated ICH E6(R3) guideline.  

“Using AI in clinical research doesn’t necessarily require tearing up your existing quality system,” says Wartenberger. What it means is added checks for AI bias and drift—two of the main operational and ethical risks in working with machine learning systems. 

Moreover, “accountability can’t be delegated to technology,” he continues. People must understand what being accountable means as well as be able to evidence their AI-supported decisions, as was discussed by panelists Megan Olberding, head of U.S. operations for clinical data management at MSD, and Charlotte Byng, director of solutions consulting at Fortrea.  

It’s hard to be accountable for what you don’t understand, was an added point made by panelist Aurora Rojo Sanchís, head of the GCP and Good Pharmacovigilance Practice (GVP) Inspection Area of the Spanish Agency for Medicines and Medical Devices. A good first step, therefore, is training on the specific AI tool being used and the risks that come along with it.     

All too often, Wartenberger says, a human-in-the-loop approach that “looks strong on paper … fails in practice.” “We have a huge opportunity to offload things [to AI] that may be tedious or repetitive, but that should free up our cognitive ability to focus on the things that matter.” Blindly accepting AI output can cause major risks.  

Based on his personal experience working with CRIO clients, data privacy and protection are two of the biggest concerns in the clinical research industry. “Just plugging [highly sensitive] data into an AI tool without adequate protections in place would be a terrible mistake. You can get into hot water very quickly if you don’t understand the implications of misusing that data, potentially with a free version of any of the publicly available AI tools,” he said.    

On the safe side are sanctioned versions of tools that have undergone your vendor assessment process and have been deemed acceptable for a particular use case. “You might even want to use AI to read and understand the lengthy privacy policy of another AI tool,” Wartenberger says. In his day-to-day work at CRIO, he uses a sanctioned internal AI tool to quickly query answers to customer and client questions regarding the company’s policies and procedures or to compose a summary of one of its sections (e.g., business continuity process).   

Regulatory Patchwork  

Relative to AI tools, validation of traditional software is much more of a “one and done” proposition unless the system changes, says Wartenberger. “With AI, it’s constantly evolving and improving and learning, so the concept of validation is shifting and … different approaches might be needed to ensure the model [always] does what it’s intended to do.” 

Quotient